Just got this email from Roche announcing a grant program to pay registration and travel fees for the AGBT meeting if you are using Roche-454 sequencing or Roche-Nimblegen arrays as part of your work (see below). Seems like this would have some of the same conflict of interest issues as a pharma company paying someone to give a talk. I note - I participated in a session supported by 454 at a meeting but paid my own way to avoid this type of conflict of interest issue. Anyone have opinions on this? Is this a common pharma method creeping its way more and more into genomics?
Subscribe to:
Post Comments (Atom)
Most recent post
A ton to be thankful for -- here is one part of that - all the acknowledgement sections from my scholarly papers
So - it is another Thanksgiving Day and in addition to thinking about family, and football, and Alice's Restaurant, I also think a lot a...
-
I have a hardback version of The Bird Way by Jennifer Ackerma n but had not gotten around to reading it alas. But now I am listening to th...
-
There is a spreading surge of PDF sharing going on in relation to a tribute to Aaron Swartz who died a few days ago. For more on Aaron ...
-
Wow. Just wow. And not in a good way. Just got an email invitation to a meeting. The meeting is " THE FIRST ANNUAL WINTER Q-BIO ...

Interesting post - I hadn't considered being sponsored by the makers of a piece of equipment you use to be much of a conflict of interest (although admittedly I am newish to the world of scientific conferences). I can see it being a problem if your abstract is basically "Roche equipment is amazing" but do you think it is also a problem if the abstract is "using roche equipment we found..." ?
ReplyDeleteIf you did receive the grant isn't it normal practice to write this on your poster/say it in your presentation? That would point out any possible conflict of interest to your audience. Or do you think that is not enough?